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Abstract
Background: The prevalence of obesity is surging in an alarming rate all over the world. Pharmaceutical drugs are
considered potential adjunctive therapy to lifestyle modification. However, for most, besides being too expensive,
their long term usages are hindered by their severe adverse effects. Here we describe the effect of UP601, a
standardized blend of extracts from Morus alba, Yerba mate and Magnolia officinalis, in modulating a number
of obesity-related phenotypic and biochemical markers in a high-fat high-fructose (HFF)-induced C57BL/6J
mouse model of obesity.
Method: Adipogenesis activity of the composition was assessed in 3T3-L1 cells in vitro. Effects of UP601 on
body weight and metabolic markers were evaluated. It was administered at oral doses of 300 mg/kg, 450 mg/kg and
600 mg/kg for 7 weeks. Orlistat (40 mg/kg/day) was used as a positive control. Body compositions of mice were
assessed using dual energy X-ray absorptiometry (DEXA). Serum biomarkers were measured for liver function and lipid
profiling. Relative organ weights were determined. Histopathological analysis was performed for non-alcoholic
steatohepatitis (NASH) scoring.
Results: UP601 at 250 μg/ml resulted in 1.8-fold increase in lipolysis. Statistically significant changes in body
weight (decreased by 9.1, 19.6 and 25.6% compared to the HFF group at week-7) were observed for mice
treated with UP601 at 300, 450 and 600 mg/kg, respectively. Reductions of 9.1, 16.9, and 18.6% in total cholesterol; 45.0,
55.0, 63.6% in triglyceride; 34.8, 37.1 and 41.6% in LDL; 3.2, 21.6 (P = 0.03) and 33.7% (P = 0.005) in serum glucose were
observed for UP601 at 300, 450 and 600 mg/kg, respectively. Body fat distribution was found reduced by 31.6 and
17.2% for the 450 mg/kg UP601 and orlistat, respectively, from the DEXA scan analysis. Up to an 89.1% reduction in
mesenteric fat deposit was observed for UP601 in relative organ weight. Statistically significant improvements in NASH
scores were observed for mice treated with UP601.
Conclusion: UP601, a standardized botanical composition from Morus alba, Yerba mate and Magnolia officinalis could
potentially be used for achieving healthy weight loss and maintenance.
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Background
According to recent epidemiologic reports, the preva-
lence of obesity is surging at an alarming rate all over
the world. For example, a recent study pooling data
from 186 countries from 1975–2014, reported that the
global obesity rates increased from 3.2% in 1975 to
10.8% in 2014 in men and from 6.4% in 1975 to 14.9%
in 2014 in women [1]. Unless the current trends are
reversed, it will incur significant impact on global
health and the economy. It is mainly caused by an
imbalance between energy intake and expenditure
complicated by a sedentary lifestyle in association with
easy access to a highly palatable, energy-dense diet
rich in fat, sugar and salt. Untreated it can result in
dyslipidemia, cardiovascular disease (including hyper-
tension, stroke, and myocardial infarction), insulin re-
sistance, impaired glucose metabolism, osteoarthritis
and some cancers [2].
While maintaining an optimum bodyweight may seem
to be a sound solution to counteract obesity, for most
individuals, achieving lifestyle modifications becomes an
uphill battle once they are obese. At this point, pharma-
ceutical drugs are considered potential adjunctive treat-
ment to lifestyle modification. However, the lack of
sustainable weight loss, cost and adverse effects render
current pharmacotherapy weight management unsuc-
cessful. Therefore, in light of the limited pharmaceutical
drug choices and the socio-economic implications of the
obesity pandemic, the search for safe and effective alter-
natives from natural sources has gained appeal within
the dietary supplement industry. In this regard, we pos-
tulated that combining plant materials with similar tradi-
tional usage and safety data would give a beneficial
boost in their indication for treatment of metabolic dis-
orders. To test this hypothesis, we recently screened a
series of plant extracts collected through legacy mining
in vivo for their metabolic disorder related activities using
a high-fat diet (HFD)-induced mouse obesity model which
led to the discovery of a composition designated as
UP601. UP601 is composed of standardized extracts from
Morus alba, Ilex paraguariensis and Magnolia officinalis.
These botanicals are particularly attractive because they
have a long history of safe consumption, and also may
provide other added health benefits beyond weight con-
trol. Previously we have reported the appetite suppression
and anti-obesity effects of this composition in acute feed
intake rat model and high-fat diet (HFD)-induced obese
C57BL/6J mouse model [3].
Morus alba L (Family: Moraceae), the mulberry or
white berry plant, is native to northern China, and has
been cultivated and naturalized elsewhere, from India
through the middle east to Southern Europe, and re-
cently to North American. The root-bark of Morus
alba that is used in traditional medicine is known as
Sang Bai Pi or Cortex Mori (Pharmacopoeia of the
People’s Republic of China, 2005). This herb is also
known as Pong-na-moo in Korean and Sohakuhi in Japan.
In contemporary pharmacological research, Morus alba
root-bark has been reported to have antibacterial [4], anti-
oxidant and hypoglycemic [5, 6] hypolipidemic, neuropro-
tective, antiulcer, analgesic [7–9] and anti-inflammatory
activities [10]. Some of the prenylated flavonoids and stil-
benoids such as morusin and mulberroside A are unique
to Morus plants [11].
Yerba mate (Family: Aquifoliaceae, botanical name:
Ilex paraguariensis A. St.-Hil) is a widely-cultivated,
medium-sized evergreen tree indigenous to Paraguay,
Brazil, Argentina, and Uruguay; however, it is now cul-
tivated in many tropical countries to supply a world de-
mand for its leaves. As a folk medicine, it has been
used to suppress appetite, stimulate digestion, and as
an antioxidant. Its chemical constituents were isolated
and identified as xanthines, polyphenols, caffeoyl deriv-
atives and saponins [12]. It has been reported to have
antioxidant [13], lipid lowering [14], anti-cancer [15]
and anti-diabetic properties [16].
Magnolia officinalis Rehder & E.H. Wilson (Family:
Magnoliaceae) has long been traditionally used as a
Chinese medicinal herb for the treatment of fever, head-
ache, anxiety, diarrhea, stroke, and asthma. Honokiol
and magnolol are considered as the two major bioactive
constituents [17] and have been reported with various
biological effects such as anti-inflammatory and anal-
gesic [18], smooth muscle relaxant and antithrombotic
[19, 20] treatment of diabetes and diabetic complications
[21], inhibition of the formation of advanced glycation
end products (AGEs) [22], antidepressant [23], anti-cancer
[24] and as antioxidants [25].
It has been reported that the co-administration of
high-fat and high-carbohydrate diet in animals leads to
the development of typical metabolic complications
present in human metabolic syndrome including obesity,
hyperglycemia, dyslipidemia (exhibited as hypertriglyc-
eridemia, hypercholesterolemia), and fatty liver [26, 27].
Hence, an obesity model induced by feeding the combin-
ation of high-fat with high-fructose instead of the high-
fat or high-fructose diet alone may provide a better tool
to understand the mechanisms involved in disease initi-
ation and progression as it simulates the current
calorie-rich diet of the western world. To the best of
our knowledge, until recently, the disclosed plant mate-
rials have never been formulated together for weight
management indications. The present study was there-
fore designed to assess the effect of a specific blend of
these extracts on modulating a number of obesity-
related phenotypic and biochemical markers in a high-
fat and high-fructose (HFF)-induced C57BL/6J mouse
model of obesity.
Yimam et al. BMC Complementary and Alternative Medicine  (2017) 17:114 Page 2 of 12
Methods
Material preparation
Detailed procedures of composition matter prepara-
tions have been described on US patent application
entitled “COMPOSITIONS AND METHODS FOR
MANAGING WEIGHT” with publication number:
20140004215.
Dried bark of Magnolia officinalis and dried root bark
of Morus alba were collected from Chongqing, China and
identified by professor Shou-Yuen Zhao from Si-Chuan
Chinese Traditional Medicine Research Institutes. A
voucher of specimen of Magnolia officinalis (P00491) and
Morus alba (P00329) were deposited at the plant library
of Unigen, Seattle, WA, USA. When re-collected,
Magnolia officinalis barks and Morus alba root barks
were always characterized and confirmed in compari-
son with the original voucher specimens. Dried Ilex
paraguayensis leaves extracts were obtained from Naturex
(NJ, USA).
UP601 is a proprietary blend of standardized extracts
from Magnolia officinalis stem bark, Morus alba root
bark, and Ilex paraguariensis leaf with not less than 7%
magnolol and honokiol, 2% caffeine, and 1% total biofla-
vonoids including kuwanon G and albanin G and
morusin.
Morus alba root bark extract was produced by 70%
ethanol extraction of the ground root bark powder with
no less than 10% total bioflavonoids including kuwanon
G, albanin G, and morusin. Magnolia officinalis stem
bark was extracted by a supercritical fluid and further
crystalized to give a mixture of magnolol and honokiol
with content higher than 95%. Ilex paraguayensis leaf
was extracted with water to give Yerba Mate extract
containing not less than 4% caffeine. The dried powders
of Magnolia officinalis stem bark extract, Morus Alba
root bark extract, and Ilex paraguariensis leaves extracts
were mixed at a proprietary ratio to produce the stan-
dardized UP601 composition.
Effects of UP601 in 3T3-L1 cells
3T3-L1 murine embryo fibroblast cells were purchased
from American Type Culture Collection (Rockville, MD).
Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (GIBCO) containing 10% bovine calf serum until
confluent. Two days after post confluence (D0), the cells
were stimulated to differentiate with DMEM containing
10% fetal bovine serum (FBS), 5 μg/ml insulin, 0.5 mM 3-
isobutyl-1-methylxanthine (IBMX) and 1 μM dexametha-
sone for two days (D2). Cells were then maintained in 10%
FBS/DMEM medium with 5 μg/ml insulin for another two
days (D4), followed by culturing with 10% FBS/DMEM
medium for four days (D8). To determine the extent of
lipolysis induced by UP601, fully differentiated adipo-
cytes (mature adipocytes) were treated with UP601, at
250 μg/ml, for 24 h and 48 h with serum free DMEM.
The conditioned medium was removed from each well
and free glycerol was assayed by using a Lipolysis assay
kit (#F6428, Sigma-Aldrich Inc., USA) following the
manufacturer’s instructions.
Induction and intervention
The study was designed and executed in a high-fat and
high-fructose (HFF) diet-induced obesity model to simu-
late the western pattern diet [28]. Mice were provided
with 60% high-fat diet (Research diet D12492, Doo Yeol
Biotech) and 30% fructose (ADM CORNSWEET®, ADM,
USA, Lot; AE14032911) in water ad libitum. After 5-
weeks on the HFF, a 23% increase in body weight gain
was observed and deemed mice were ready for treatment
intervention. Mice were then randomized into six
groups: 1) normal control + vehicle (N = 7, Normal diet,
Research diet D12450B), 2) HFF + vehicle (N = 7), 3)
HFF +Orlistat (N = 7, 40 mg/kg), 4) HFF + UP601 low
dose (N = 7, 300 mg/kg), 5) HFF +UP601 mid dose (N = 7,
450 mg/kg), 6) HFF +UP601 high dose (N = 7, 600 mg/kg)
and administrations were initiated orally twice per day
and sustained for 7 weeks.
The vehicle-treated animals received 0.15% xanthan
gum + 0.5% Tween 80 only. The positive control,
Orlistat (Lipidown Cap 120 mg, Lot #12003, Hanmi,
Korea), N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-
oxo-2-oxetanyl]methyl]dodecyl ester, with a trade name
of Xenical or Alli, is a Food and Drug Administration-
approved human pancreatic lipase inhibitor, which
inhibits the absorption of approximately one third of
fat from ingested food that would ultimately result in
weight reduction.
Water for the normal control group or fructose-
enriched water for the vehicle and treatment groups was
provided ad libitum. Animals were maintained in a
temperature and air flow controlled room (22.2 °C,
and 10–15 filtered air changes per hour, respectively)
on a 12-h light–dark cycle with a relative humidity of
50 °C ± 10. Feed and water consumption was measured
twice a week throughout treatment period. To better
estimate calorie intake by mice, instead of 5 mice/cage, as
of week 6, each mouse was placed in an individual cage
for the whole treatment duration. All animal experiments
were conducted according to institutional guidelines
congruent with the guide for the care and use of labora-
tory animals under Institutional Animal Care and Use
Committees (IACUC) Approval No.: UIK21407.
Body composition analysis using DEXA
After 5 weeks of treatment, representative mice (2 mice
from each group) were selected from the normal con-
trol, HFF, 450 mg/kg UP601 and Orlistat groups and
were subjected to dual energy X-ray absorptiometry
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(DEXA, InAlyzer™ MEDIKORS, Korea) for body com-
position. The system was calibrated according to manu-
facturer’s instructions prior to the start of the experiment.
Software integrated to the scan was used for data analysis.
DEXA uses two separate low-dose X-ray exposures to
read bone and soft tissue mass with a high degree of
precision.
Blood chemistry analysis for liver function and lipid profiles
At necropsy day, mice were fasted for 16 h and approxi-
mately 0.6 ~ 0.9 mL of blood sample were collected from
the abdominal vein. Samples were centrifuged and
serum was transferred to Biotoxtech Co., Ltd. for liver
function and lipid profiles analysis. Serum levels of ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), total cholesterol (T-Chol), triglycerides (TG), LDL-
cholesterol (LDL-C), HDL- cholesterol (HDL-C) and
glucose were measured using a Hitachi auto-analyzer
(7180, HITACHI, Japan).
Necropsy and tissue collection for histopathology
On the last day of the assay, all animals were exsangui-
nated and examined for gross pathology. Once the ab-
dominal cavity was opened, organs were subjected to
gross examination. Liver, and visceral fat pads (epididymal,
retroperitoneal, peri-renal fat pad and mesenteric fat) were
collected and weighed individually for organ-to-body
weight ratio determination then specimens were fixed
with 10% buffered neutral formalin, trimmed, proc-
essed, embedded in paraffin, sectioned, and stained
with Hematoxylin & Eosin (H&E) for microscopic
NASH (non-alcoholic steatohepatitis) score analysis
according to the modified scoring system method of
Kleiner DE et al. [29].
Statistical analysis
All non-discrete data from clinical chemistry, body weight
and food consumption were represented as mean ± S.D
and were analyzed using Sigmaplot (Version 11.0). Statis-
tical significance between groups was calculated by means
of single factor analysis of variance followed by a paired
t-test. P-values less or equal to 0.05 (P ≤ 0.05) were
considered as significant. When normality tests failed,
data for non-parametric analysis were subjected to
Mann–Whitney sum ranks for t-test and Kruskal-Wallis
one way analysis of variance on ranks for ANOVA. Inter-
pretations of the results were made based on findings
from the in-life body weights, DEXA scan, serum bio-
markers and NASH score.
Results
Lipolytic effects of UP601 in 3T3-L1 cells
Up to 1.8-fold increase in the amount of glycerol re-
leased into the media was observed in adipocytes treated
with UP601 for 24 h and 48 h. The lipolytic effect of
UP601 was time dependent. The significant increase in
glycerol release was observed after 24 h of treatment
(Fig. 1).
Effect of UP601 on body weight
Rapid body weight gain was observed when C57BL/6J
mice were fed a 60% Kcal High-Fat-Diet and 30% fruc-
tose enriched water ad libitum for 5 weeks. Mice were
transferred to a ‘mini-cage’ that houses a single mouse
Fig. 1 Lipolytic effect of UP601 in 3T3-L1 adipocytes. Fully differentiated adipocytes were treated with UP601 at 250 μg/ml for 24 and 48 h.
Lipolysis was assessed by the amount of glycerol released into media in treated adipocytes
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per cage for the treatment duration. After 5-weeks on
the HFF, a 23% increase in body weight gain was ob-
served and deemed mice were ready for randomization
for treatment intervention and treatment was initiated.
As seen in Fig. 2, a statistically significant rapid drop
in body weight was observed for mice treated with
40 mg/kg/day of Orlistat for the first two weeks of the
treatment period followed by a moderate body weight
gain compared to vehicle treated HFF group. In contrast,
mice treated with UP601 showed a dose-correlated very
stable, minimal body weight gain throughout the duration
of treatment. In particular, mice treated with the high dose
of UP601 showed 6.4% reductions in body weight when
compared to baseline. Compared to the vehicle-treated
HFF group, body weight gains for mice treated with
UP601 were significantly lower after 3 weeks for the
600 mg/kg/day group and after 5 weeks for the
450 mg/kg/day group, and these differences remained
statistically significant for the rest of treatment dur-
ation. Statistically non-significant reductions in body
weight were observed for mice treated with 300 mg/kg
UP601. The percent changes in body weight at week-7
compared to week-0 (baseline) were found to be 6.4%
for normal control diet, 27.3% for HFF, 2.0% for HFF +
Orlistat, 14.5% for HFF + 300 mg/kg UP601, 1.3% for
HFF + 450 mg/kg UP601, and −6.4% for HFF +
600 mg/kg UP601 (Fig. 2). When these changes were
computed against the HFF group, it was found that
mice treated with the composition UP601 showed dose
correlated reductions of 9.1% for 300 mg/kg UP601, 19.6%
for 450 mg/kg UP601 and 25.6% for 600 mg/kg UP601 at
the end of the seven week treatment period. The positive
control, Orlistat, resulted in 19.0% reduction in body
weight compared to vehicle-treated HFF-fed mice (Fig. 2).
Effect of UP601 on liver and lipid biomarkers
Abnormal lipid metabolism and excessive lipid accumu-
lation in tissues are cardinal features of obesity as a re-
sult of consumption of high-fat in combination with
high-fructose diet. The serum glucose, total cholesterol,
triglyceride and LDL-cholesterol levels of mice in the
HFF group were found to be 35.9, 67.2, 131.9 and
217.9% higher compared to regular diet-fed mice at the end
of study, respectively (Table 1). As depicted in Table 1, the
UP601 composition restored altered metabolic disturbances
as demonstrated by serum liver enzymes and lipid panel
levels to near normal. Mice treated with UP601 showed 9.1,
16.9 and 29.8% reductions in total cholesterol, 45.0, 55.0,
63.6% reductions in triglyceride, 34.8, 37.1 and 41.6%
reductions in LDL for the 300 mg/kg, 450 mg/kg and
600 mg/kg groups, respectively, compared to vehicle-
treated HFF-fed mice (Table 1). These reductions were all
statistically significant compared to vehicle-treated HFF-fed
mice for all the dosages except for the 300 mg/kg reduction
in the total cholesterol. Improvement in dyslipidemia
seemed to appear dose correlated.
Hyperglycemia is one of the characteristic manifesta-
tions of metabolic disorder. Treatment with UP601
Fig. 2 Body weight changes observed after 7 weeks of daily oral UP601 treatment in HFF fed obese C57BL/6J mice. HFF-induced obese C57BL/6J mice
were treated with UP601 at oral doses of 300, 450 and 600 mg/kg for 7-weeks. Orlistat (ORI) at 40 mg/kg was used as a reference compound.
N = 7 for each group; **P ≤ 0.0001 compared to HFF group; †P ≤ 0.001 compared to HFF group; *P ≤ 0.05 compared to HFF group
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reversed the abnormal glucose level near to the normal
control mice fed a regular diet. Reductions of 3.2, 21.6
(P = 0.03) and 33.7% (P = 0.005) in serum glucose level
were observed for mice treated with UP601 at oral doses
of 300 mg/kg, 450 mg/kg and 600 mg/kg, respectively,
compared to the HFF group. In contrast, mice treated
with Orlistat showed a 56.9% increase in serum trigly-
ceride, 15.0%, 17.9% (P = 0.01) and 43.8% (P = 0.005)
reductions in glucose, total cholesterol and LDL, re-
spectively, compared to vehicle treated HFF (Table 1).
Alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) are the two primary liver enzymes fre-
quently used to determine liver damage. Treatment with
UP601 resulted in substantial reductions in these en-
zymes in serum. 46.1, 45.3, and 62.7% reductions in ALT
and 18.0, 8.7 and 16.3% reductions in AST levels were
observed for mice treated with 300 mg/kg, 450 mg/kg
and 600 mg/kg of UP601, respectively, compared to
vehicle-treated HFF-fed mice (Table 1). Mice treated
with Orlistat showed, 53.0 and 21.3% reductions in ALT
and AST, respectively, compared to vehicle-treated HFF
(Table 1).
Effect of UP601 on body composition and relative organ
weight
It has been reported that mice fed HFF to develop meta-
bolic disorder manifested by increased abdominal fat
deposition, impaired glucose tolerance, dyslipidemia,
hyperinsulinemia, and increased systolic blood pressure
[30, 31]. Abdominal fat deposit was effectively reduced
by the mid and high dose of UP601. As seen in Table 2,
the mid and high dose of UP601 efficiently decreased
epididymal, retro-peritoneal, peri-renal and mesenteric
fat deposit compared to vehicle-treated HFF group. It
was found that mice treated with 450 mg/kg and
600 mg/kg UP601 had 23.4 and 77.3% reductions in epi-
didymal fat, 9.5 and 75.1% reductions in retro-peritoneal
fat, 44.4 and 87.8% reductions in peri-renal fat, and 50.0
and 89.1% reductions in mesenteric fat deposit, respect-
ively, compared to vehicle treated HFF. While the effects
on the epididymal, retro-peritoneal, and peri-renal fat
deposits were minimal for mice treated with 300 mg/kg
of UP601, a notable 27.9% reduction in the mesenteric
fat deposit was observed for this group, compared to ve-
hicle treated HFF. As expected, mice fed the HFF
showed 3.96-, 3.84-, 4.13-, and 3.14-fold increase in epi-
didymal, retro-peritoneal, peri-renal and mesenteric fat
deposits, respectively, in comparison to the regular diet
control mice. The epididymal, retro-peritoneal, peri-
renal and mesenteric fat loss in the Orlistat-treated mice
were 17.0, 16.6, 34.3 and 42.8%, respectively, compared
to the vehicle-treated HFF group (Table 2).
Limited representative dual energy X-ray absorptiometry
(DEXA) scan was performed to determine the lean body
Table 1 Liver function and lipid profiling
Group Dose (mg/kg) ALT (U/L) AST (U/L) Glucose (mg/dL) T-chol (mg/dL) TG (mg/dL) LDL-C (mg/dL) HDL-C (mg/dL)
NC 0 21.6 ± 1.7 45.3 ± 13.8 206.4 ± 46.6* 101.1 ± 17.4‡ 14.1 ± 3.4† 2.8 ± 0.8‡ 57.6 ± 10.4*
HFF 0 36.2 ± 21.3 58.2 ± 10.0 280.6 ± 54.6 169.4 ± 17.2 32.7 ± 11.3 8.9 ± 2.4 69.5 ± 3.4
ORI 40 17.0 ± 2.2* 45.8 ± 4.2* 238.6 ± 69.0 139.1 ± 18.0† 51.3 ± 27.1 5.0 ± 1.2† 68.6 ± 6.2
UP601 300 19.5 ± 4.8 47.7 ± 4.2* 271.3 ± 35.4 153.9 ± 9.5 18.0 ± 9.4* 5.8 ± 0.5† 65.2 ± 3.7*
UP601 450 19.8 ± 12.2 53.1 ± 19.6 219.9 ± 35.1* 140.7 ± 16.5† 14.7 ± 6.1† 5.6 ± 0.9† 65.1 ± 4.1
UP601 600 16.5 ± 7.5* 48.7 ± 19.1 186.1 ± 47.1† 118.9 ± 21.0‡ 11.9 ± 4.8† 5.2 ± 1.2† 57.7 ± 10.5*
HFF-induced obese C57BL/6J mice were treated with UP601 at oral doses of 300, 450 and 600 mg/kg for 7-weeks. Orlistat (ORI) at 40 mg/kg was used as a reference
compound. Serum samples were collected at necropsy. ALT alanine aminotransferase, AST aspartate aminotransferase, T-chol total cholesterol, TG triglycerides, LDL C
low-density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol. NC Normal control + vehicle, HFF HFF + Vehicle, ORI HFF + orlistat, UP601 HFF + indicated
concentrations of UP601. *P ≤ 0.05 compared to HFF group; †P ≤ 0.001 compared to HFF group; ‡P ≤ 0.0001 compared to HFF group
Table 2 Relative organ weight for mice treated with UP601 in HFH-induced mouse obesity model
Group Liver (%) Fat deposit (%)
Epididymal Retroperitoneal Peri-Renal Mesenteric Total
NC 3.39 ± 1.47 1.75 ± 0.33‡ 0.44 ± 0.14‡ 0.24 ± 0.10‡ 0.81 ± 0.15‡ 3.22 ± 0.67‡
HFF 3.17 ± 0.47 6.93 ± 1.06 1.69 ± 0.30 0.99 ± 0.20 2.76 ± 0.97 12.36 ± 1.17
ORI (40) 3.21 ± 0.12 5.75 ± 1.59 1.41 ± 0.38 0.65 ± 0.17† 1.58 ± 0.64* 9.38 ± 2.63*
UP601 (300) 2.83 ± 0.14 6.82 ± 0.64 1.68 ± 0.14 0.82 ± 0.17 1.99 ± 0.48 11.31 ± 0.92
UP601 (450) 2.96 ± 0.16 5.31 ± 1.04* 1.53 ± 0.29 0.55 ± 0.12‡ 1.38 ± 0.24 8.76 ± 1.54‡
UP601 (600) 2.99 ± 0.17 1.57 ± 1.57† 0.42 ± 0.42* 0.12 ± 0.12‡ 0.30 ± 0.30† 2.41 ± 2.41‡
HFF-induced obese C57BL/6J mice were treated with UP601 at oral doses of 300, 450 and 600 mg/kg for 7-weeks. Orlistat (ORI) at 40 mg/kg was used as a reference
compound. Tissue collections were carried out at necropsy. NC Normal control + vehicle, HFF HFF + Vehicle, ORI HFF + orlistat, UP601 HFF + indicated concentrations of
UP601 (mg/kg). * P ≤ 0.05 compared to HFF group; † P ≤ 0.001 compared to HFF group; ‡ P ≤ 0.0001 compared to HFF group
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and fat mass distribution of sedated mice (Fig. 3). The per-
cent body fat distribution for the HFF group was 161.5% to
that of the regular diet-fed normal control group. There
was no difference in the lean mass between groups.
However, compared to HFF, 31.6 and 17.2% reductions
in fat deposit were observed for mice treated with the
mid-dose of UP601 and Orlistat, respectively. The
DEXA images seemed to support the body weight data.
Mice in the UP601 group appeared leaner than the orli-
stat or the HFF mouse.
Effect of UP601 on liver histopathology
Quick onsets of lipid accumulation accompanied with
vacuolation are the common histopathological phenomena
observed in the liver when mice are fed HFF. Histology
analysis of H&E stained liver sections from the HFF groups
[Fig. 4b] of mice exhibited enlargement of hepatocytes and
steatosis represented by the vacuolation and microvesicular
fat droplets in hepatocytes in comparison with those in the
normal control mice [Fig. 4a]. Mice in the HFF group de-
veloped severe steatosis, lobular inflammation and hepato-
cellular ballooning. While there did not appear to be a
difference in degree of steatosis between the HFF and
UP601 groups [specially for the 300 mg/kg (Fig. 4d) and
600 mg/kg (Fig. 4f)], significantly improved NASH scores
(P = 0.02, 0.01, and 0.02 for the 300 mg/kg, 450 mg/kg and
600 mg/kg, respectively) summing the effect of UP601 in
steatosis, lobular inflammation and hepatocellular bal-
looning were observed compared to vehicle treated
HFF group (Figs. 4 and 5). In particular, no hepatocellu-
lar ballooning was observed for mice treated with the
high dose of UP601 (Fig. 4f ). There was no obvious dif-
ference between the normal control and the mid-dose
group of UP601 with regard to liver histology (Fig. 4e).
Similarly, statistically significant improvement in the
NASH score was also noted for the Orlistat group com-
pared to vehicle treated HFF group (Figs. 4c and 5).
Discussion
Excessive fat intake and consumption of soft drinks
loaded with high-fructose are closely associated with in-
creased prevalence of metabolic syndrome and may lead
to non-alcoholic fatty liver disease (NAFLD) [32–34].
The past few decades’ diet westernization has resulted in
significant increases in daily calorie intake because of
the added fructose to easily accessible cheap food and
soft drinks. For example, the typical daily consumption
of fructose has escalated from 16–20 g per day (mostly
from fresh fruits) to 85–100 g per day (mainly in the
form of high-fructose corn syrup) within the past three
decades [35]. The exposure of the liver to such a high
extent of fructose could lead to rapid stimulation of lipo-
genesis and hepatocyte triglyceride accumulation [36].
Consumed together with fat, it renders the dietary fruc-
tose and dietary fat to serve as sources for endogenous
[37] and exogenous lipids [38], and their co-presence
exacerbates the prevalence of metabolic disorder. For
the purpose of this simulation, the animal model was de-
veloped by feeding mice a diet containing a combination
of a 60% high-fat diet with 30% fructose in water (HFF)
for 5 weeks. In the current study the biochemical and
biological activity of a well-defined composition, UP601,
has been evaluated using this very well-established ani-
mal model of obesity that mimics human metabolic
disorder exhibited as a result of consumption of the so-
called western diet. For screening, a legacy mining ap-
proach was used to search Medline, pharmacopeia of
traditional Chinese medicine, Ayurveda medicine, and
our Phytologix collection database for plants that have po-
tential for weight management and metabolic disorder-
related indications, which led to the discovery of UP601.
Data depicted in the present study demonstrate that
exposure to a combination of high-fat diet and free ac-
cess to fructose in the drinking water led mice to exhibit
apparent phenotypes of metabolic syndrome, including
increased body weight, dyslipidemia and increased blood
Fig. 3 DEXA scan images for mice in the HFF-induced obesity group. HFF-induced obese C57BL/6J mice were treated with UP601 at oral doses
of 300, 450 and 600 mg/kg for 7-weeks. Orlistat (ORI) at 40 mg/kg was used as a reference compound. NC: Normal control + vehicle; HFF: HFF + Vehicle;
ORI: HFF + orlistat; HFF + 450 mg/kg UP601
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glucose level, confirming the role of the two high calorie
dietary factors in the increased prevalence of obesity and
metabolic syndrome. A 56.8% increase in body weight
was observed for vehicle-treated mice fed HFF compared
to vehicle-treated regular diet-fed normal control mice
at the end of the study. Much of this weight gain is be-
lieved to be a result of excessive visceral fat deposit.
High-fat diets and high-fructose diets have been shown
to produce more rapid weight gain in rodents [39]. In
contrast, these conditions were moderated by oral
treatment of UP601. For example, mice treated with
UP601 showed a reduced body weight gain and improved
metabolic performance compared to vehicle treated HFF
fed mice. These body weight reductions were analyzed
and were found to be 9.1, 19.6 and 25.6% for mice treated
with UP601 at oral doses of 300, 450 and 600 mg/kg, re-
spectively, when compared to the vehicle treated HFF-fed
group at week 7. Within the same treatment period, the
Orlistat group had a 19.0% reduction in body weight com-
pared to HFF. Almost complete prevention of body weight
Fig. 4 H&E staining of liver tissue. 200x magnification. a Normal control; b HFF; c HFF +Orlistat treated; d HFF + 300 mg/kg UP601; e HFF + 450 mg/kg
UP601; f HFF + 600 mg/kg treated
Fig. 5 Non-alcoholic Steato-Hepatitis (NASH) Scores for mice in the HFF study group treated with Orlistat (40 mg/kg) and UP601 (300 mg/kg,
450 mg/kg and 600 mg/kg). N = 7 for each group, ***P ≤ 0.0001 compared to HFF group; **P ≤ 0.001 compared to HFF group;*P ≤ 0.05 compared
to HFF group
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gain was observed in those groups that received higher
doses (450 and 600 mg/kg) of UP601. Compared to
week-0 (treatment start), the mid-dosage (450 mg/kg)
of the composition maintained the initial treatment
start body weight throughout the course of the treat-
ment with only 1.3% body weight gain; the high dose
(600 mg/kg) resulted in a 6.4% reduction from the ini-
tial body weight of treatment start compared to the end
of treatment period. For comparison, the HFF group
gained a 27.3% and the Orlistat group gained 2% of
their treatment start initial body weight.
Compromised lipid metabolism and lipid accumula-
tion in tissues are cardinal features of obesity as a result
of consumption of high-fat in combination with high-
fructose. As demonstrated by the liver histology and
clinical chemistry data, UP601 treatment mitigated these
abnormal changes. Treatments of HFF diet-induced
obese mice with UP601 for 7 weeks significantly reduced
total cholesterol, LDL, and triglyceride. Moreover, the
hyperglycemia observed in the mice fed HFF was
moderated to the level of the normal control mice fed
regular rodent diet by the oral treatment of UP601.
These findings are in accordance with the reported data
for individual constituents of the composition. Thus,
UP601 appears to possess additional beneficial effects in
regulation of dyslipidemia and management of healthy
blood glucose.
Liver, as a regulator of glucose and lipid metabolism, is
the primary organ to be affected by continual insult
from high calorie loading that could lead to fatty liver.
In particular, nonalcoholic fatty liver disease exhibits a
wide spectrum of indexes ranging from steatosis alone,
steatosis with inflammation, steatosis with hepatocyte in-
jury, or steatosis with sinusoidal fibrosis in relation to
stages of disease progression [40, 41]. Many of these ab-
normal alterations were observed in vehicle-treated mice
fed HFF under histopathology examinations. However,
mice treated with UP601 showed significantly improved
NASH scores in lobular inflammation and hepatocellular
ballooning without affecting the liver enzymes (AST and
ALT) suggesting the composition may have an indication
in fatty liver disease without associated adverse effects.
In fact, previously, Morus extract has been shown to re-
duce plasma triglycerides, hepatic fat accumulation and
epididymal adipocyte size after a 12-week treatment
period in HFD-induced obese mice [42]. Comparable
findings were also observed for Yerba mate in that a de-
crease in the accumulation of lipids in adipocytes, and
reductions in serum cholesterol, serum triglycerides, and
glucose concentrations were reported when adminis-
tered orally to high-fat diet-fed C57BL/6J mice daily at
doses of 0.5 – 2 g/kg for 4-weeks [16].
Visceral fat deposit is one of the characteristic mani-
festations of obesity. In our study, mice in the UP601
group physically appeared leaner than vehicle-treated
HFF-fed mice. This was demonstrated by the relative
organ weight data. Mice in this group had statistically
significantly reduced epididymal, retroperitoneal, peri-
renal and mesenteric fat deposits, with the largest de-
crease in fat mass occurring in the mesenteric deposits,
which was 89.1% (for 600 mg/kg UP601) less than the
vehicle-treated HFF mice. This implies that the rapid in-
crease in body weight observed in the HFF-fed mice
could be as the result of visceral fat accumulation. It can
also be inferred that the significant reductions in body
weight noted for mice treated with UP601 could also be
due to minimal visceral fat deposition. In fact, the repre-
sentative data from the DEXA scan support these obser-
vations in that the reduction in body weight may be a
result of low body fat accumulation.
Noteworthy anti-adipogenic effects were also observed
for the composition in vitro. UP601 stimulates lipolysis
in 3T3-L1 adipocytes. This finding is consistent with the
reduced preliminary body fat distribution data from the
DEXA scan and relative organ weights for visceral fat.
Previously it has been reported for Yerba mate to inhibit
adipogenesis [43] and triglyceride accumulation in 3T3-
L1 adipocytes [44]. Extracts from another component of
the composition, Magnolia, have also effectively reduced
lipid accumulation in 3T3-L1 adipocytes [45]. Moreover,
extracts from M. alba have also shown inhibitory effects
in the proliferation and differentiation of preadipocytes
[46] and the accumulation of triglyceride in 3T3-L1 cells
[47]. Thus, the anti-obesity effect observed in the
current study could partially be explained by the lipolytic
activity of UP601.
Furthermore, augmented studies have been docu-
mented in relation to Morus, Magnolia and Yerba mate
plant extracts that contain bioactive compounds posses-
sing metabolic disease-modifying activities beneficial to
the effects observed in the present study. For example,
extracts from Magnolia have shown decreases in fasting
blood glucose and plasma insulin in type 2 diabetic rats
[48], amelioration of body fat accumulation, insulin re-
sistance, and adipose inflammation in high-fat fed mice
[49], stimulation of glucose uptake in insulin-sensitive
and insulin-resistant murine and human adipocytes
using the insulin signaling pathway [50], and control of
elevated stress-related cortisol level [51] in human. The
beneficial moderation in body weight and metabolic
markers observed in the current study could partially be
explained by the inherent activities of Magnolia extract
contributing to the composition as described in this
summary.
Likewise, significant studies have also demonstrated
that Yerba mate extracts alleviates weight gain and im-
proves plasma glucose and lipid profiles in animals [52].
It has been reported that HFD-induced obese mice
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treated orally with Yerba mate extract for 8 weeks at a
dose of 1 g/kg displayed a marked attenuation of weight
gain and adiposity, a decrease in epididymal fat pad
weight, and restoration of the serum levels of choles-
terol, triglycerides, LDL cholesterol, and glucose. These
results were identical to what were observed in our
study. Additionally, significantly lowered body weight,
visceral fat-pad weights, blood and hepatic lipid, glucose,
insulin, and leptin levels were observed in HFD rats
treated with a Yerba mate extract formulated diet for
60-days [53]. Here, again, the composition UP601 might
be assumed to adapt the suggested mechanism of action
and activities of Yerba mate as shown by data depicted
in the current study.
The impact of Morus extracts in metabolic disorders
like diabetes and obesity have also been reported. Signifi-
cantly low body weight gain [42], improved hypergly-
cemia and associated complications in the diabetic rats
[54], decreased body weight, adiposity, and hepatic lipid
accumulation in diet-induced obese mice [55], decreased
expression of white muscle adipocytokines in db/db
mice [56] and blood glucose level in alloxan diabetic
mice [57] are some of the beneficial effects documented
for this plant. Previously, it has also been reported that
Morus extract increases adiponectin level in adipocytes
[58], increases glucose uptake and GLUT4 translocation
in adipocytes [58], and inhibits α-glucosidase [59] and
intestinal disaccharidase [60] activity. In support of the
other two components of the composition, Morus ex-
tract also reinforces the potential of UP601 in weight
management as a result of the collective mechanisms of
action contributed by all the three components. There-
fore, the data depicted in the current study ensures the
merit of combining these plant extracts for a better out-
come targeting multiple pathways that are indicated in
various aspects of metabolic disorders.
The current study was not without a limitation. While
the combination of fructose from drinking water and
high-fat diet was assumed to cause accelerated body
weight gain, the actual calorie intake from food and the
drinking water per day per animal could not be accur-
ately determined due to the spillage of water from the
Lixit. As a result, the proportion of weight gain to the
change in calorie intake due to treatment could not be
confirmed. Another limitation for this study was the
number of animals per group selected for DEXA scan.
Only two animals per group were analyzed for body
composition. The 300 mg/kg and 600 mg/kg UP601
were excluded from the body composition analysis.
Hence, meaningful quantitative fat and lean mass data
to support the relative organ weight findings could not
be generated.
Although the multiple mechanisms by which UP601
may impact lipid and carbohydrate metabolism are
plausible according to its individual components in vitro
and in vivo studies from the literature, further additional
studies are needed to determine the possible thermogenic
(contribution from Yerba mate), lipolytic (contribution
from all three components) and anorectic (contribution
from Morus and Magnolia) effects of the composition.
Conclusion
To sum up, we have demonstrated the anti-obesity activity
of a standardized composition UP601 from the historically
well-known plants: Morus alba, Yerba mate and Magnolia
officinalis. Oral administration of UP601 to high-fat and
high-fructose-fed mice for 7 weeks resulted in a significant
reduction in body weight gain. The composition also
moderated dyslipidemia and hyperglycemia in vivo and
acted as a lipolytic in vitro. While pre-clinical to clinical
data translation requires human clinical trial validation
and safety study, the data depicted here in conjunction
with the individual components’ safe historical usage
suggest UP601 could potentially be considered as a
natural alternative for metabolism management and main-
taining a healthy body weight.
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